Navigation Links
hERG-CHO K1 Recombinant Cell Line from Upstate

ProductshERG-CHO K1 Recombinant Cell Line from Upstate
Company Upstate
Item hERG-CHO K1 Recombinant Cell Line
Description PrecisION Ion Channel Cell Lines
High Quality, Functionally-Validated, Ion Channel Cell Lines

Ion channels are well known for having a critical role in nerve and muscle function and consequently have a key function in pain, CNS and the heart. Drugs that modulate ion channels have been investigated in therapeutic areas, such as neuropathic pain, cardiac arrhythmia, hypertension, local anaesthesia, stroke, Parkinson's, obesity, epilepsy, diabetes and depression.

Historically, ion channels have been under exploited as drug targets primarily due to the lack of functional high throughput screening technologies. Over recent years, there has been considerable progress in this important area. However, now there is a requirement for high quality research tools that will allow the full benefit of the new screening technologies to be realised. Upstate has built a portfolio of ion channel cell lines to meet these new and evolving needs in the drug discovery industry.

Our ion channel cell lines are available off of the shelf. These cell lines are fully validated using electrophysiology, stable (>25 passage) and licensed for drug discovery research. The objective is to provide the pharmaceutical industry with a range of ion channel cell lines to support drug discovery, lead optimisation and safety pharmacology functions.
Info UpstateUpstate
28820 Single Oak Drive
Temecula, CA 92590
Customer Service: 800-437-7500 or 951-676-8080
Tech Support: 800 548-7853
Fax Number: 800-437-7502 or 951-676-9209
Web Site:
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. hERG-CHO K1 Recombinant Cell Line from Upstate
2. Recombinant Expression of Peptides and Proteins: from rPeptide, LLC
3. Recombinant RNasin® Ribonuclease Inhibitor from Promega
4. GeneChoice RNA Safe Recombinant Ribonuclease Inhibitor from GeneChoice, Inc.
5. RNaseOUT Recombinant Ribonuclease Inhibitor from Invitrogen
6. hKv4.2/hKChIP2-CHO K1 Recombinant Cell Line from Upstate
7. hHCN4-CHO K1 Recombinant Cell Line from Upstate
8. hKv1.5-CHO K1 Recombinant Cell Line from Upstate
9. hNav1.6-HEK293 Recombinant Cell Line from Upstate
10. hKvLQT1/hminK-CHO K1 Recombinant Cell Line from Upstate
11. Smac/DIABLO, Human, Recombinant, E. coli from Calbiochem
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
Biology Products:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
Breaking Biology Technology: